GlassScriptPhysician profile
Brandy Michelle Long
NPI 1497255160
$2,908.24
in general payments reported to CMS, 2019-2025
16 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2024: $701 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670 · Travel and Lodging: $974 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.38 |
| Travel and Lodging | $974.30 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,394.55 | 2024-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $269.19 | 2024-2025 | Wegovy, Ozempic |
| Alkermes, INC. | $215.09 | 2025 | Aristada, Lybalvi |
| Insulet Corporation | $182.16 | 2024-2025 | Omnipod |
| Argenx US, INC. | $148.04 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $142.47 | 2024-2025 | Zepbound, Mounjaro |
| Genentech USA, INC. | $118.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $115.35 | 2021 | |
| Tandem Diabetes Care, INC. | $92.25 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $88.28 | 2024 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.21 | 2025 | Caplyta |
| Pharmacosmos Therapeutics INC. | $20.08 | 2024 | Monoferric |
| Teva Pharmaceuticals USA, INC. | $19.72 | 2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Dexcom, INC. | $13.64 | 2024 | Dexcom G6 Transmitter |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.